Business
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the A
About this update from Ocular Therapeutix, Inc.
[{"type":"image","alt":"Ocular Therapeutix, Inc.","displaySize":"","headline":null,"caption":"Ocular Therapeutix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jQkRmXXuVY17YPwf6FJ8wQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f","width":300,"height":101}},"lazy":false},{"type":"text","content":"First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment","length":155,"tagName":"p"},{"type":"text","content":"Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm","length":177,"tagName":"p"},{"type":"text","content":"65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm","length":142,"tagName":"p"},{"type":"text","content":"Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52","length":89,"tagName":"p"},{"type":"text","content":"55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0013) compared to aflibercept (2 mg) subjects ","length":176,"tagName":"p"},{"type":"text","content":"77.1% of AXPAXLI subjects randomized in SOL-1 would have been rescue-free at Week 24 using SOL-R rescue criteria which align closely with clinical practice","length":155,"tagName":"p"},{"type":"text","content":"AXPAXLI was generally well-tolerated in SOL-1 with no treatment-related ocular SAEs ","length":83,"tagName":"p"},{"type":"text","content":"Subjects have been re-dosed at Week 52","length":38,"tagName":"p"},{"type":"text","content":"Ocular plans to submit New Drug Application (NDA) based on SOL-1 data, subject to planned formal discussions with U.S. FDA ","length":122,"tagName":"p"},{"type":"text","content":"Conference call and webcast today, February 17, 2026, at 8:00 AM ET, to discuss topline data","length":92,"tagName":"p"},{"type":"text","content":"Detailed data to be presented at 49th Macu...